¶ Experiment: Sleep and Circadian Dysfunction in Neurodegeneration
Rank: 112
Is sleep disruption a causal driver of neurodegeneration or merely a downstream marker, and can sleep/circadian restoration slow disease progression?
Sleep disturbances are nearly universal in neurodegenerative diseases, affecting 40-90% of patients with AD, PD, and other disorders. Key questions remain:
- Does sleep disruption cause neurodegeneration or result from it?
- What is the temporal relationship - does poor sleep predict faster decline?
- Can therapeutic sleep optimization modify disease trajectory?
- H1: Chronic sleep fragmentation causally contributes to protein aggregation (impaired glymphatic clearance)
- H2: Circadian disruption accelerates tau phosphorylation and propagation
- H3: Sleep optimization (pharmacological or behavioral) will reduce neurodegeneration biomarkers
- H4: Sleep phenotypes define distinct disease subtypes with different progression rates
Cohort Structure:
| Group |
N |
Criteria |
| Subjective cognitive decline with sleep complaints |
100 |
Poor sleep, no objective impairment |
| MCI with sleep disorder |
75 |
MCI + PSG-confirmed disorder |
| Early AD/PD |
100 |
Mild disease + sleep complaints |
| Age-matched good sleep controls |
75 |
Normal sleep, no neurodegenerative signs |
Assessments (annual for 4 years):
- Sleep measures:
- Polysomnography (PSG) - full, at baseline and 2 years
- Actigraphy (14 days quarterly)
- Sleep diaries
- Epworth Sleepiness Scale, PSQI
- Neurodegeneration biomarkers:
- CSF: Aβ42/40, p-tau181, total tau, α-syn SAA, NfL
- Plasma: NfL, p-tau217, GFAP
- Amyloid PET (Florbetaben)
- Tau PET (MK-6240) in AD cohort
- Dopaminergic PET (FP-CIT) in PD cohort
- Cognitive/motor:
- AD: MoCA, RBANS, Clinical Dementia Rating
- PD: MDS-UPDRS, Hoehn & Yahr
- Primary: Change in neurodegeneration biomarkers per unit of sleep disruption
- Secondary: Does sleep improvement correlate with biomarker stabilization?
- Tertiary: Define sleep-phenotype subtypes within each disease
- Sleep deprivation in 5xFAD mice (amyloid model)
- Sleep fragmentation in P301S tau mice
- Circadian disruption in MPTP/6-OHDA PD model
- Glymphatic clearance assays under sleep-deprived conditions
- Circadian clock gene knockdown in neuronal cultures
- Causality determination: Establish whether sleep is causal vs. correlative
- Mechanistic insight: Map sleep → protein clearance pathway dysfunction
- Intervention targets: Identify optimal sleep/circadian interventions
- Subtype definition: Sleep phenotypes as disease subtypes
- Year 1: Enrollment complete, baseline biomarkers + PSG
- Year 2: First longitudinal data, sleep-biomarker correlations emerge
- Year 3: Test causality with cross-sectional and longitudinal models
- Year 4: Intervention arm results, mechanistic validation
| Dimension |
Score |
Rationale |
| Mechanistic Impact |
9/10 |
Addresses fundamental question of sleep-neurodegeneration relationship |
| Cure Proximity |
7/10 |
Sleep interventions are low-risk; could slow progression |
| Feasibility |
8/10 |
Standard sleep and biomarker techniques; multi-site |
| Cost Efficiency |
8/10 |
Sleep interventions are inexpensive |
| Timeline |
7/10 |
4-year study reasonable |
| Cross-Disease Value |
10/10 |
Applicable to AD, PD, ALS, FTD, all neurodegenerative diseases |
| Biomarker Enablement |
9/10 |
Sleep measures are biomarkers; correlates with progression |
| Combinability |
9/10 |
Sleep intervention can combine with all disease-modifying approaches |
| De-risking Value |
8/10 |
Low-risk intervention could benefit millions |
| Novelty |
8/10 |
First comprehensive multi-disease sleep-neurodegeneration study |
Total Score: 83/100
| Item |
Cost |
| Polysomnography (baseline + 2yr) |
$1,200,000 |
| Biomarker analysis (CSF + plasma) |
$1,800,000 |
| PET imaging |
$1,500,000 |
| Actigraphy and sleep monitoring |
$400,000 |
| Clinical assessments |
$600,000 |
| Data management and analysis |
$500,000 |
| Total |
$6,000,000 |
- Nedergaard M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013.
- Musiek ES, et al. Circadian clock proteins and neurodegeneration. Nat Rev Neurosci. 2020.
- Ju YE, et al. Sleep and neurodegeneration: A critical appraisal. Lancet Neurol. 2023.